{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:27:07Z","timestamp":1782390427335,"version":"3.54.5"},"reference-count":140,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T00:00:00Z","timestamp":1589587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Several indole derivatives have been disclosed by our research groups that have been collaborating for nearly 25 years. The results of our investigations led to a variety of molecules binding selectively to different pharmacological targets, specifically the type A \u03b3-aminobutyric acid (GABAA) chloride channel, the translocator protein (TSPO), the murine double minute 2 (MDM2) protein, the A2B adenosine receptor (A2B AR) and the Kelch-like ECH-associated protein 1 (Keap1). Herein, we describe how these works were conceived and carried out thanks to the versatility of indole nucleus to be exploited in the design and synthesis of drug-like molecules.<\/jats:p>","DOI":"10.3390\/molecules25102331","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T11:34:14Z","timestamp":1589801654000},"page":"2331","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Exploiting the Indole Scaffold to Design Compounds Binding to Different Pharmacological Targets"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8675-939X","authenticated-orcid":false,"given":"Sabrina","family":"Taliani","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Pisa, Via Bonanno Pisano, 6, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Da Settimo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pisa, Via Bonanno Pisano, 6, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-3027","authenticated-orcid":false,"given":"Claudia","family":"Martini","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pisa, Via Bonanno Pisano, 6, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Laneri","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Naples \u201cFederico II\u201d, Via D. Montesano, 49, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Novellino","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Naples \u201cFederico II\u201d, Via D. Montesano, 49, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Greco","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Naples \u201cFederico II\u201d, Via D. Montesano, 49, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"782","DOI":"10.2174\/138955709788452649","article-title":"From nature to drug discovery: The indole scaffold as a \u2018privileged structure\u2019","volume":"9","author":"Fraga","year":"2009","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_2","first-page":"291","article-title":"International Union of Pharmacology. XV. Subtypes of \u03b3-aminobutyric acidA receptors: Classification on the basis of subunit structure and receptor function","volume":"50","author":"Barnard","year":"1998","journal-title":"Pharmacol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00441-006-0284-3","article-title":"GABA(A) Receptor diversity and pharmacology","volume":"326","author":"Mohler","year":"2006","journal-title":"Cell Tissue Res."},{"key":"ref_4","first-page":"795","article-title":"Subunit composition, distribution and function of GABA(A) receptor subtypes","volume":"326","author":"Sieghart","year":"2006","journal-title":"Cell Tissue Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1124\/pr.117.014449","article-title":"International Union of Basic and Clinical Pharmacology. CVI: GABAA receptor subtype- and function-selective ligands: Key issues in translation to humans","volume":"70","author":"Sieghart","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2174\/1568026023393507","article-title":"Subunit composition, distribution and function of GABA(A) receptor subtypes","volume":"2","author":"Sieghart","year":"2002","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.300.1.2","article-title":"A New benzodiazepine pharmacology","volume":"300","author":"Mohler","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1359-6446(03)02703-X","article-title":"GABA-A receptor subtypes in the brain: A paradigm for CNS drug discovery?","volume":"8","author":"Whiting","year":"2003","journal-title":"Drug Discovery Today"},{"key":"ref_9","first-page":"670","article-title":"Functional characterization of human \u03b3-aminobutyric acidA receptors containing the \u03b14 subunit","volume":"50","author":"Wafford","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9676","DOI":"10.1523\/JNEUROSCI.0513-15.2015","article-title":"\u03b16-Containing GABAA receptors are the principal mediators of inhibitory synapse strengthening by insulin in cerebellar granular cells","volume":"35","author":"Accardi","year":"2015","journal-title":"J. Neurosci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2174\/1568026023393444","article-title":"Mapping of the benzodiazepine recognition site on GABAA receptors","volume":"2","author":"Sigel","year":"2002","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2174\/138161280505230110100242","article-title":"Ligands for the benzodiazepine binding site-a survey","volume":"5","author":"Teuber","year":"1999","journal-title":"Curr. Pharm. Des."},{"key":"ref_13","first-page":"51","article-title":"Interpretation of behavioral effects of benzodiazepine receptor ligands","volume":"14","author":"Gardner","year":"1989","journal-title":"Drugs Future"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/328221a0","article-title":"Sequence and functional expression of the GABAA receptor shows a ligand-gated receptor super-family","volume":"328","author":"Schofield","year":"1987","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/335076a0","article-title":"Structural and functional basis for GABAA receptor heterogeneity","volume":"335","author":"Levitan","year":"1988","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1096\/fasebj.4.5.2155149","article-title":"Molecular biology of GABAA receptor","volume":"4","author":"Olsen","year":"1990","journal-title":"FASEB J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1096\/fasebj.5.14.1661244","article-title":"GABAA receptor subtypes: From pharmacology to molecular biology","volume":"5","author":"Burt","year":"1991","journal-title":"FASEB J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/75761","article-title":"Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor \u03b11 subtype","volume":"3","author":"McKernan","year":"2000","journal-title":"Nat. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev.pharmtox.44.101802.121429","article-title":"Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics","volume":"44","author":"Rudolph","year":"2004","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharmthera.2004.04.003","article-title":"Regulation of GABAA receptor trafficking, channel activity, and functional plasticity of inhibitory synapses","volume":"102","author":"Keller","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.coph.2005.10.003","article-title":"GABA-based therapeutic approaches: GABAA receptor subtype functions","volume":"6","author":"Rudolph","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.2174\/092986707782023190","article-title":"GABAA\/Bz receptor subtypes as targets for selective drugs","volume":"14","author":"Taliani","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1021\/jm00382a022","article-title":"Specific inhibition of benzodiazepine receptor binding by some N-(indol-3-ylglyoxylyl)amino acid derivatives","volume":"28","author":"Martini","year":"1985","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1073\/pnas.77.4.2288","article-title":"Urinary and brain \u03b2-carboline carboxylates as potent inhibitors of brain benzodiazepine receptors","volume":"77","author":"Braestrup","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1021\/jm00132a004","article-title":"Specific inhibition of benzodiazepine receptor binding by some N-(indol-3-ylglyoxylyl)amino acid derivatives: Stereoselective interactions","volume":"32","author":"Primofiore","year":"1989","journal-title":"J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1021\/jm00090a011","article-title":"Benzodiazepine receptor affinity and interaction of some N-(indol-3-ylglyoxylyl)amine derivatives","volume":"35","author":"Bianucci","year":"1992","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0223-5234(97)86173-9","article-title":"Isosteric replacement of the indole nucleus by benzothiophene and benzofuran in a series of indolylglyoxylylamine derivatives with partial agonist activity at the benzodiazepine receptor","volume":"31","author":"Lucacchini","year":"1996","journal-title":"Eur. J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1021\/jm960240i","article-title":"Synthesis, structure-activity relationships, and molecular modeling studies of N-(indol-3-ylglyoxylyl)benzylamine derivatives acting at the benzodiazepine receptor","volume":"39","author":"Primofiore","year":"1996","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1021\/jm9800301","article-title":"N\u2019-Phenylindol-3-ylglyoxylohydrazide derivatives: Synthesis, structure-activity relationships, molecular modeling studies and pharmacological action on brain benzodiazepine receptors","volume":"41","author":"Primofiore","year":"1998","journal-title":"J. Med. Chem."},{"key":"ref_30","first-page":"171","article-title":"The Cambridge Structural Database","volume":"B72","author":"Groom","year":"2016","journal-title":"Acta Cryst."},{"key":"ref_31","first-page":"193","article-title":"Development of a comprehensive pharmacophore model for the benzodiazepine receptor","volume":"12","author":"Zhang","year":"1995","journal-title":"Drug. Des. Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1021\/jm010827j","article-title":"Novel N-(arylalkyl)indol-3-ylglyoxylamides targeted as ligands of the benzodiazepine receptor: Synthesis, biological evaluation, and molecular modeling analysis of the structure-activity relationships","volume":"44","author":"Primofiore","year":"2001","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1021\/jm0511841","article-title":"Refinement of the benzodiazepine receptor site topology by structure-activity relationships of new N-(heteroarylmethyl)indol-3-ylglyoxylamides","volume":"49","author":"Primofiore","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1021\/jm0607707","article-title":"Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1\/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-selective ligands","volume":"50","author":"Primofiore","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1021\/jm990341r","article-title":"Pharmacophore\/receptor models for GABAA\/BzR subtypes (\u03b11\u03b23\u03b32, \u03b15\u03b23\u03b32, and \u03b16\u03b23\u03b32) via a comprehensive ligand-mapping approach","volume":"43","author":"Huang","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_36","first-page":"131","article-title":"Pharmacophore\/receptor models for GABAA\/BzR \u03b12\u03b23\u03b32, \u03b13\u03b23\u03b32, and \u03b14\u03b23\u03b32 recombinant subtypes. Included volume analysis and comparison to \u03b11\u03b23\u03b32, \u03b15\u03b23\u03b32, and \u03b16\u03b23\u03b32","volume":"17","author":"He","year":"2000","journal-title":"Drug Des. Discov."},{"key":"ref_37","first-page":"186","article-title":"Studies in search of \u03b12 Selective ligands for GABAA\/BzR receptor subtypes. Part I. Evidence for the conservation of pharmacophoric descriptors for DS subtypes","volume":"9","author":"Yu","year":"1999","journal-title":"Med. Chem. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2174\/156802611795371350","article-title":"GABAA receptor subtype-selective modulators. I. \u03b12\/\u03b13-Selective agonists as non-sedating anxiolytics","volume":"11","author":"Atack","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1021\/jm9001154","article-title":"Identification of anxiolytic\/nonsedative agents among indol-3-ylglyoxylamides acting as functionally selective agonists at the \u03b3-aminobutyric acid-A (GABAA) \u03b12 benzodiazepine receptor","volume":"52","author":"Taliani","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0091-3057(89)90033-6","article-title":"Exploration of mice in a black and white test box: Validation as a model of anxiety","volume":"32","author":"Costall","year":"1989","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0968-0004(02)02092-3","article-title":"Anxiety over GABA(A) receptor structure relieved by AChBP","volume":"27","author":"Cromer","year":"2002","journal-title":"Trends Biochem. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/266732a0","article-title":"Benzodiazepine receptors in rat brain","volume":"266","author":"Squires","year":"1977","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.tips.2006.06.005","article-title":"Translocator protein (18 kDa): New nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function","volume":"27","author":"Papadopoulos","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.mce.2015.03.014","article-title":"Translocator protein-mediated pharmacology of cholesterol transport and steroidogenesis","volume":"408","author":"Papadopoulos","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Fan, J., and Papadopoulos, V. (2013). Evolutionary origin of the mitochondrial cholesterol transport machinery reveals a universal mechanism of steroid hormone biosynthesis in animals. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076701"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1042\/BCJ20170766","article-title":"Translocator protein and steroidogenesis","volume":"475","author":"Costa","year":"2018","journal-title":"Biochem. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/bpa.12196","article-title":"The 18 kDa translocator protein, microglia and neuroinflammation","volume":"24","author":"Liu","year":"2014","journal-title":"Brain Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nrd3295","article-title":"Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders","volume":"9","author":"Rupprecht","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Da Pozzo, E., Tremolanti, C., Costa, B., Giacomelli, C., Milenkovic, V.M., Bader, S., Wetzel, C.H., Rupprecht, R., Taliani, S., and Da Settimo, F. (2019). Microglial pro-inflammatory and anti-inflammatory phenotypes are modulated by translocator protein activation. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184467"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1210\/endo.139.12.6390","article-title":"Peripheral-type benzodiazepine receptor function in cholesterol transport. Identification of a putative cholesterol recognition\/interaction amino acid sequence and consensus pattern","volume":"139","author":"Li","year":"1998","journal-title":"Endocrinology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"860","DOI":"10.2174\/156802611795165142","article-title":"Structural requirements to obtain highly potent and selective 18 kDa translocator protein (TSPO) ligands","volume":"11","author":"Taliani","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_52","first-page":"1160","article-title":"Site-directed mutagenesis of the peripheral benzodiazepine receptor: Identification of amino acids implicated in the binding site of Ro5-4864","volume":"46","author":"Farges","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/0024-3205(83)90063-2","article-title":"Peripheral benzodiazepine binding sites: Effect of PK11195, 1-(2-chlorophenyl)-N-methyl-(1-methylpropyl)-3-isoquinolinecarboxamide. II. In vivo studies","volume":"32","author":"Guilloux","year":"1983","journal-title":"Life Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1042\/BST20150028","article-title":"Targeting the 18-kDa translocator protein: Recent perspectives for neuroprotection","volume":"43","author":"Giacomelli","year":"2015","journal-title":"Biochem. Soc. Trans."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.2174\/092986709789057653","article-title":"Translocator protein ligands as promising therapeutic tools for anxiety disorders","volume":"16","author":"Taliani","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.1175055","article-title":"Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects","volume":"325","author":"Rupprecht","year":"2009","journal-title":"Science"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2174\/156802612799078720","article-title":"Translocator protein as a promising target for novel anxiolytics","volume":"12","author":"Costa","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.pnpbp.2009.05.018","article-title":"Lack of tolerance to anxiolysis and withdrawal symptoms in mice repeatedly treated with AC-5216, a selective TSPO ligand","volume":"33","author":"Kita","year":"2009","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hup.757","article-title":"Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: A doubleblind controlled study in general practice","volume":"21","author":"Nguyen","year":"2006","journal-title":"Hum. Psychopharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1021\/jm030973k","article-title":"N,N-Dialkyl-2-phenylindol-3-ylglyoxylamides. a new class of potent and selective ligands at the peripheral benzodiazepine receptor","volume":"47","author":"Primofiore","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1021\/jm8003224","article-title":"Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis","volume":"51","author":"Simorini","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1021\/jm00072a010","article-title":"Chemistry, binding affinity, and behavioral properties of a new class of \u201cantineophobic\u201d mitochondrial DBI receptor complex (mDRC) ligands","volume":"36","author":"Kozikowski","year":"1993","journal-title":"J. Med. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.psyneuen.2010.07.021","article-title":"Anxiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity","volume":"36","author":"Costa","year":"2011","journal-title":"Psychoneuroendocrinology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/156802612799078766","article-title":"Medicinal chemistry of indolylglyoxylamide TSPO high affinity ligands with anxiolytic-like effects","volume":"12","author":"Simorini","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1021\/acs.jmedchem.5b00689","article-title":"Deepening the topology of the translocator protein binding site by novel N,N-dialkyl-2-arylindol-3-ylglyoxylamides","volume":"58","author":"Barresi","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1126\/science.1248725","article-title":"Structure of the mitochondrial translocator protein in complex with a diagnostic ligand","volume":"343","author":"Jaremko","year":"2014","journal-title":"Science"},{"key":"ref_67","unstructured":"This code univocally identifies the quoted protein. PDB code: 2MGY."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Da Pozzo, E., Giacomelli, C., Costa, B., Cavallini, C., Taliani, S., Barresi, E., Da Settimo, F., and Martini, C. (2016). TSPO PIGA ligands promote neurosteroidogenesis and human astrocyte well-being. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17071028"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejps.2016.04.006","article-title":"TSPO-ligands prevent oxidative damage and inflammatory response in C6 glioma cells by neurosteroid synthesis","volume":"88","author":"Santoro","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1021\/jm061137o","article-title":"New fluorescent 2-phenylindolglyoxylamide derivatives as probes targeting the peripheral type benzodiazepine receptor: Design, synthesis, and biological evaluation","volume":"50","author":"Taliani","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1021\/jm100100q","article-title":"Novel irreversible fluorescent probes targeting the 18 kDa translocator protein: Synthesis and biological characterization","volume":"53","author":"Taliani","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/acel.12200","article-title":"Genetic analysis of dTSPO, an outer mitochondrial membrane protein, reveals its functions in apoptosis, longevity, and Ab42-induced neurodegeneration","volume":"13","author":"Lin","year":"2014","journal-title":"Aging Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1021\/jm101230g","article-title":"Evaluation of novel N1-methyl-2-phenylindol-3-ylglyoxylamides as a new chemotype of 18 kDa translocator protein-selective ligand suitable for the development of positron emission tomography radioligands","volume":"54","author":"Pike","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_74","first-page":"387","article-title":"Is there any correlation between binding and functional effects at the translocator protein (TSPO) (18 kDa)?","volume":"12","author":"Scarf","year":"2012","journal-title":"Curr. Mol. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nrd2082","article-title":"Drug-target residence time and its implications for lead optimization","volume":"5","author":"Copeland","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"18164","DOI":"10.1038\/srep18164","article-title":"TSPO ligand residence time: A new parameter to predict compound neurosteroidogenic efficacy","volume":"6","author":"Costa","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/cmdc.201700220","article-title":"Residence time, a new parameter to predict neurosteroidogenic efficacy of translocator protein (TSPO) ligands: The case study of N,N-dialkyl-2-arylindol-3-ylglyoxylamides","volume":"12","author":"Costa","year":"2017","journal-title":"ChemMedChem"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1021\/acschemneuro.6b00149","article-title":"Long residence time at the neurosteroidogenic 18 kDa translocator protein characterizes the anxiolytic ligand XBD173","volume":"7","author":"Costa","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1021\/acschemneuro.7b00027","article-title":"The anxiolytic etifoxine binds to TSPO Ro5\u22124864 binding site with long residence time showing a high neurosteroidogenic activity","volume":"8","author":"Costa","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1021\/acschemneuro.9b00300","article-title":"Unbinding of Translocator Protein 18 kDa (TSPO) Ligands: From in Vitro Residence Time to in Vivo Efficacy via in Silico Simulations","volume":"10","author":"Bruno","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_81","first-page":"4722","article-title":"Designed multiple ligands for cancer therapy","volume":"18","author":"Meegan","year":"2001","journal-title":"Curr. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2174\/092986708783503212","article-title":"From single- to multi-target drugs in cancer therapy: When aspecificity becomes an advantage","volume":"15","author":"Petrelli","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1517\/14656560902781907","article-title":"Multitarget drugs: The present and the future of cancer therapy","volume":"10","author":"Petrelli","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"534","DOI":"10.2174\/1389450117666160301095233","article-title":"Polypharmacology of Approved Anticancer Drugs","volume":"18","author":"Amelio","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.2174\/138161211797249251","article-title":"Bioenergetics pathways and therapeutic resistance in gliomas: Emerging role of mitochondria","volume":"17","author":"Griguer","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nm.3076","article-title":"Apoptosis therapy: Driving cancers down the road to ruin","volume":"19","author":"Green","year":"2013","journal-title":"Nat. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd3137","article-title":"Targeting mitochondria for cancer therapy","volume":"9","author":"Fulda","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.biocel.2013.03.004","article-title":"The translocator protein (TSPO): A novel target for cancer chemotherapy","volume":"45","author":"Austin","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/cbic.200400350","article-title":"PIGA (N,N-di-n-butyl-5-chloro-2-(4-chlorophenyl)indol-3-ylglyoxylamide), a new mitochondrial benzodiazepine-receptor ligand, induces apoptosis in C6 glioma cells","volume":"6","author":"Chelli","year":"2005","journal-title":"ChemBioChem"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s13277-013-0871-3","article-title":"Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme","volume":"34","author":"England","year":"2013","journal-title":"Tumor Biol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Villalonga-Planells, R., Coll-Mullet, L., Martinez-Soler, F., Castano, E., Acebes, J.J., Gimen\u00e9z-Bonaf\u00e9, P., Gil, J., and Tortosa, A. (2011). Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018588"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-moleculea ntagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1038\/srep04749","article-title":"Apoptosis therapy in cancer: The first single-molecule coactivating p53 and the translocator protein in glioblastoma","volume":"4","author":"Daniele","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1021\/acs.jmedchem.5b01767","article-title":"Lead optimization of 2-phenylindolylglyoxylyldipeptide murine double minute (MDM)2\/translocator protein (TSPO) dual inhibitors for the treatment of gliomas","volume":"59","author":"Daniele","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.canlet.2012.04.023","article-title":"Breast cancer stem cells: Obstacles to therapy","volume":"338","author":"Smalley","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/1535-7163.MCT-13-0966","article-title":"In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing","volume":"13","author":"Lee","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"7866","DOI":"10.18632\/oncotarget.6872","article-title":"Long lasting MDM2\/translocator protein modulator: A new strategy for irreversible apoptosis of human glioblastoma cells","volume":"7","author":"Daniele","year":"2016","journal-title":"Oncotarget"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.bbamcr.2019.01.012","article-title":"Long lasting inhibition of Mdm2-p53 interaction potentiates mesenchymal stem cell differentiation into osteoblasts","volume":"1866","author":"Daniele","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.110.003285","article-title":"International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update","volume":"63","author":"Fredholm","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbamem.2010.12.017","article-title":"Recent developments in adenosine receptor ligands and their potential as novel drugs","volume":"1808","author":"Muller","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0898-6568(03)00058-5","article-title":"Signalling from adenosine receptors to mitogen-activated protein kinases","volume":"15","author":"Schulte","year":"2003","journal-title":"Cell. Signal."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrd1983","article-title":"Adenosine receptors as therapeutic targets","volume":"5","author":"Jacobson","year":"2006","journal-title":"Nat. Rev. Drugs Discov."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1021\/jm991131h","article-title":"3-Aryl-[1,2,4]triazino [4,3-a]benzimidazol-4(10H)-ones: Tricyclic heteroaromatic derivatives as a new class of benzodiazepine receptor ligands","volume":"43","author":"Primofiore","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ardp.200300788","article-title":"Geometrically constrained analogues of N-benzylindolylglyoxylylamides: [1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one derivatives as potential new ligands at the benzodiazepine receptor","volume":"336","author":"Primofiore","year":"2003","journal-title":"Arch. Pharm."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1021\/jm00346a002","article-title":"2-Arylpyrazolo[4,3-c]quinolin-3-ones: A novel agonist, a partial agonist and an antagonist of benzodiazepines","volume":"25","author":"Yokoyama","year":"1982","journal-title":"J. Med. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1021\/jm00400a022","article-title":"Structure-activity profile of novel triazoloquinazoline adenosine antagonists","volume":"31","author":"Francis","year":"1988","journal-title":"J. Med. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1021\/jm001054m","article-title":"3-Aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: A new class of selective A1 adenosine receptor antagonists","volume":"44","author":"Primofiore","year":"2001","journal-title":"J. Med. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ddr.10366","article-title":"A1 adenosine receptor antagonists, 3-aryl[1,2,4]triazino[4,3-a]benzimidazol-4-(10H)-ones (ATBIs) and N-alkyl and N-acyl-(7-substituted-2-phenylimidazo[1,2-a][1,3,5]triazin-4-yl)amines (ITAs): Different recognition of bovine and human binding sites","volume":"63","author":"Primofiore","year":"2004","journal-title":"Drug Dev. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1021\/jm201177b","article-title":"Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: A novel template for the design of highly selective A2B adenosine receptor antagonists","volume":"55","author":"Taliani","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-540-89615-9_4","article-title":"Recent developments in A2B adenosine receptor ligands","volume":"193","author":"Kalla","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_111","first-page":"3301","article-title":"A2B adenosine receptor signalling attenuates acute lung injury by enhancing alveolar fluid clearance in mice","volume":"118","author":"Eckle","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nm.2728","article-title":"Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia","volume":"18","author":"Eckle","year":"2012","journal-title":"Nat. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1593\/neo.08478","article-title":"Host A2B adenosine receptors promote carcinoma growth","volume":"10","author":"Ryzhov","year":"2008","journal-title":"Neoplasia"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Gao, Z.-G., and Jacobson, K.A. (2019). A2B Adenosine Receptor and Cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20205139"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1007\/s00018-005-5328-4","article-title":"TNF-alpha upregulates adenosine 2b (A2b) receptor expression and signaling in intestinal epithelial cells: A basis for A2bR overexpression in colitis","volume":"62","author":"Kolachala","year":"2005","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/bjp.2008.227","article-title":"Blockade of adenosine A2B receptors ameliorates murine colitis","volume":"155","author":"Kolachala","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1517\/13543776.16.10.1347","article-title":"A2B adenosine receptor antagonists and their potential indications","volume":"16","author":"Zablocki","year":"2006","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11302-008-9119-x","article-title":"Progress in the discovery of selective, high affinity A2B adenosine receptor antagonists as clinical candidates","volume":"5","author":"Kalla","year":"2009","journal-title":"Purinergic Signal."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.2174\/1381612825666190717105834","article-title":"Therapeutic Potentials of A2B Adenosine Receptor Ligands: Current Status and Perspectives","volume":"25","author":"Chandrasekaran","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ejmech.2013.09.001","article-title":"Modulation of A2B adenosine receptor by 1-benzyl-3-ketoindole derivatives","volume":"69","author":"Taliani","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.bbagen.2013.12.021","article-title":"Allosteric modulators of human A2B adenosine receptor","volume":"1840","author":"Trincavelli","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neuropharm.2010.07.010","article-title":"Allosteric modulation of G protein-coupled receptors: A pharmacological perspective","volume":"60","author":"Keov","year":"2011","journal-title":"Neuropharmacology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ddtec.2012.08.004","article-title":"Allosteric modulation and functional selectivity of G protein coupled receptors","volume":"10","author":"Gao","year":"2013","journal-title":"Drug Discov. Today"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1016\/j.bbamcr.2014.09.013","article-title":"Osteoblast differentiation and survival: A role for A2B adenosine receptor","volume":"1843","author":"Trincavelli","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1080\/14756366.2019.1623209","article-title":"Identification of novel indole derivatives acting as inhibitors of the Keap1-Nrf2 interaction","volume":"34","author":"Cosimelli","year":"2019","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1101\/gad.13.1.76","article-title":"Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain","volume":"13","author":"Itoh","year":"1999","journal-title":"Genes Dev."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bpobgyn.2010.10.016","article-title":"Oxidative stress","volume":"25","author":"Burton","year":"2011","journal-title":"Best. Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_128","first-page":"S128","article-title":"Direct and indirect antioxidant properties of inducers of cytoprotective proteins","volume":"52","author":"Talalay","year":"2008","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1016\/j.febslet.2005.04.058","article-title":"Role of Nrf2 signaling in regulation of antioxidants and phase 2 enzymes in cardiac fibroblasts: Protection against reactive oxygen and nitrogen species-induced cell injury","volume":"579","author":"Zhu","year":"2005","journal-title":"FEBS Lett."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"E725","DOI":"10.1073\/pnas.1508779113","article-title":"Transketolase counteracts oxidative stress to drive cancer development","volume":"113","author":"Xu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.pharmtox.43.100901.140229","article-title":"Regulatory mechanisms controlling gene expression mediated by the antioxidant response element","volume":"43","author":"Nguyen","year":"2003","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"9926","DOI":"10.1073\/pnas.91.21.9926","article-title":"Isolation of NF-E2 related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2\/AP1 repeat of the \u03b2-globin locus control region","volume":"91","author":"Moi","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"11632","DOI":"10.1016\/S0021-9258(18)99004-6","article-title":"The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity","volume":"266","author":"Rushmore","year":"1991","journal-title":"J. Biol. Chem."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/med.21257","article-title":"Small molecule modulators of Keap1\u2212Nrf2\u2212ARE pathway as potential preventive and therapeutic agents","volume":"32","author":"Magesh","year":"2012","journal-title":"Med. Res. Rev."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"10837","DOI":"10.1021\/acs.jmedchem.6b00586","article-title":"Discovery and development of Kelch-like ECH-associated protein 1. Nuclear factor erythroid 2-related factor 2 (Keap1:Nrf2) protein-protein interaction inhibitors: Achievements, challenges, and future directions","volume":"59","author":"Jiang","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1016\/j.bmc.2013.04.019","article-title":"Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism","volume":"21","author":"Marcotte","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1021\/jm4017174","article-title":"Rapid identification of Keap1-Nrf2 small-molecule inhibitors through structure-based virtual screening and hit-based substructure search","volume":"57","author":"Zhuang","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"10983","DOI":"10.1158\/0008-5472.CAN-06-2298","article-title":"Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of Nrf2 by cancer chemotherapeutic agents","volume":"66","author":"Wang","year":"2006","journal-title":"Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.chembiol.2011.03.013","article-title":"Development of Neh2-luciferase reporter and its application for high throughput screening and real-time monitoring of Nrf2 activators","volume":"18","author":"Smirnova","year":"2011","journal-title":"Chem. Biol."},{"key":"ref_140","unstructured":"This code univocally identifies the quoted protein. PDB codes: 3VNG, 3WNK, 4IFN, 4IQK, 4L7B, AL7D, 4N1B, 4L7D and 4XMB."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/10\/2331\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:29:32Z","timestamp":1760174972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/10\/2331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,16]]},"references-count":140,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["molecules25102331"],"URL":"https:\/\/doi.org\/10.3390\/molecules25102331","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,16]]}}}